OVASUITE Trademark

Trademark Overview


On Thursday, September 8, 2022, a trademark application was filed for OVASUITE with the United States Patent and Trademark Office. The USPTO has given the OVASUITE trademark a serial number of 97584013. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Friday, January 19, 2024. This trademark is owned by Aspira Women's Health Inc.. The OVASUITE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing reagent sample testing and diagnostic services for others for scientific research purposes; providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; providing medical and scientific research information; providing medical and scientific research information in the field of cancer detection and clinical trials; providing medical and scientific research information in the field of ovarian cancer detection and clinical trials; providing medical and scientific research information in the field of breast cancer detection and clinical trials; providing medical and scientific research services in the field of biomarker testing and cancer screening; medical and scientific research services in the field of cancer treatment and diagnosis; medical and scientific research services in the field of ovarian cancer treatment and diagnosis; medical and scientific research services in the field of breast treatment and diagnosis;...
ovasuite

General Information


Serial Number97584013
Word MarkOVASUITE
Filing DateThursday, September 8, 2022
Status653 - SUSPENSION LETTER - MAILED
Status DateFriday, January 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesProviding reagent sample testing and diagnostic services for others for scientific research purposes; providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; providing medical and scientific research information; providing medical and scientific research information in the field of cancer detection and clinical trials; providing medical and scientific research information in the field of ovarian cancer detection and clinical trials; providing medical and scientific research information in the field of breast cancer detection and clinical trials; providing medical and scientific research services in the field of biomarker testing and cancer screening; medical and scientific research services in the field of cancer treatment and diagnosis; medical and scientific research services in the field of ovarian cancer treatment and diagnosis; medical and scientific research services in the field of breast treatment and diagnosis; medical and scientific research services in the field of cancer treatment and diagnosis; medical and scientific research services in the fields of women's health, genetics, gynecology and cancer; scientific research consulting in the field of genetics; product development in the fields of women's health, genetics, gynecology, diagnostics and cancer; DNA analysis services for scientific research purposes; DNA screening for scientific research purposes; consulting services in the fields of laboratory testing and diagnostics; providing a web hosting platform for medical diagnostic testing, cancer diagnostic testing, gynecological diagnostic testing, and genetic testing; platform as a service (PAAS) featuring computer software platforms for diagnostic testing in the field of women's health; software as a service (SAAS) services featuring software for diagnostic testing; software as a service (SAAS) services featuring software for cancer diagnostic testing; software as a service (SAAS) services featuring software for genetic testing; software as a service (SAAS) services featuring software using artificial intelligence for medical diagnostic testing; providing on-line non-downloadable software using artificial intelligence for medical diagnostic testing, cancer diagnostic testing, gynecological diagnostic testing, and genetic testing; providing temporary use of on-line non-downloadable software and applications using artificial intelligence for medical diagnostic testing, cancer diagnostic testing, gynecological diagnostic testing, and genetic testing; providing a website featuring non-downloadable software using artificial intelligence for medical diagnostic testing, cancer diagnostic testing, gynecological diagnostic testing, and genetic testing

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, September 26, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAspira Women's Health Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAustin, TX 78738

Trademark Events


Event DateEvent Description
Monday, September 12, 2022NEW APPLICATION ENTERED
Monday, September 26, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 22, 2023ASSIGNED TO EXAMINER
Saturday, June 24, 2023NON-FINAL ACTION WRITTEN
Saturday, June 24, 2023NON-FINAL ACTION E-MAILED
Saturday, June 24, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 19, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, September 19, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, December 21, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 21, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 22, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 19, 2024SUSPENSION LETTER WRITTEN
Friday, January 19, 2024LETTER OF SUSPENSION E-MAILED
Friday, January 19, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, January 2, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION